公开(公告)号：US20150044245A1

公开(公告)日：2015-02-12

申请号：US14370454

申请日：2013-01-04

申请人： Oregon Health & Science University ,  The United States Government as represented by the Department of Veterans Affairs

发明人： Arthur A. Vandenbark ,  Gregory G. Burrows ,  Roberto Meza-Romero ,  Gil Benedek ,  Shayne Andrew ,  Jeffery Mooney

IPC分类号： C07K14/705 ,  C12Q1/68 ,  G01N33/569

CPC分类号： C07K14/705 ,  A61K39/0008 ,  A61K2039/605 ,  C07K14/70539 ,  C07K2319/74 ,  C12Q1/6881 ,  G01N33/56977 ,  G01N2333/70596 ,  G01N2500/04 ,  G01N2500/10

摘要： Disclosed herein are isolated major histocompatibility complex (MHC) class II α1 domain polypeptides and methods of use. In some embodiments, the isolated polypeptide comprises or consists of an MHC class II α1 domain polypeptide (or portion thereof) and does not include an MHC class II α2, β1, or β2 domain. The disclosed MHC class II α1 domain polypeptides are of use in treating or inhibiting disorders in a subject, such as inflammatory and/or autoimmune disorders. Also disclosed are methods of evaluating efficacy of treatment or optimizing treatment of a subject with a polypeptide including an MHC class II α1 domain polypeptide (or portion thereof) or a polypeptide including an MHC class II α1 domain and β1 domain (such as a β1α1 RTL).

摘要翻译： 本文公开了分离的主要组织相容性复合体（MHC）II型α1结构域多肽及其使用方法。 在一些实施方案中，分离的多肽包含MHC II类α1结构域多肽（或其部分）或由MHC II类α1结构域多肽（或其部分）组成，并且不包括MHC II类α2，bgr1，或bgr2结构域。 公开的MHC II类α1结构域多肽可用于治疗或抑制受试者中的疾病，例如炎性和/或自身免疫性疾病。 还公开了评估用包含MHC II类α1结构域多肽（或其部分）或包含MHC II类α1结构域和第1结构域（例如 ＆bgr;1α1RTL）。

公开(公告)号：US20220214332A1

公开(公告)日：2022-07-07

申请号：US17614271

申请日：2020-05-29

申请人： Oregon Health & Science University ,  ViTi Incorporated

发明人： Deborah Lewinsohn ,  Melissa Nyendak ,  Gwendolyn Swarbrick ,  Jeffery Mooney

IPC分类号： G01N33/50 ,  G01N33/569 ,  G01N33/68 ,  G01N33/543 ,  A61B5/00 ,  C07K7/08 ,  C07K7/06 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/133

摘要： Methods for detecting an immune response to Mycobacterium tuberculosis are provided. Aspects of the methods include contacting a biological sample comprising T cells from a subject with at least one M. tuberculosis peptide and determining the presence of T cells in the biological sample that specifically recognize the amino acid sequence of the at least one peptide, wherein the presence of T cells that specifically recognize the amino acid sequence of the at least one peptide indicates the subject has an immune response to M. tuberculosis. In certain aspects, the methods of the present disclosure may include treating a subject identified as having an immune response to M. tuberculosis. Also provided are a skin test and immunoassay kits for practicing the disclosed methods.